Evaluating Nephoxil capsules for treating high phosphate levels in kidney disease patients on dialysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and efficacy of Nephoxil capsules in patients with chronic kidney disease (CKD) who are undergoing hemodialysis and experiencing hyperphosphatemia. Participants will be monitored during their routine outpatient visits over a 48-week period, with data collected on their treatment outcomes. The initial dosage of Nephoxil will be determined by the investigator, with options for low-dose or standard-dose administration, and adjustments may be made as necessary. The study focuses on real-world clinical settings to provide insights into the medication's effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults 19 years of age or older as of the ICF date
2. CKD patients undergoing hemodialysis to whom Nephoxil capsule shall be administered for the first time for the treatment of hyperphosphatemia as per the determination of the investigator
3. Patients who voluntarily decide to participate in this study and complete the ICF

Exclusion Criteria:

1. Those who fall under the "Do not administer to the following patients" criteria according to Nephoxil capsule indication approval
2. Those who require concomitant administration of aluminum-containing medication
3. Others determined by the investigator to be unsuitable for participation in this study

Where it's running

• Jesus Hospital
  Jeonju, South Korea Recruiting

Study contacts

• Study coordinator: Clinical Study Lead
• Email: lgclinical@lgchem.com
• Phone: 82-2-6987-4112

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AP301, an iron-based phosphate binder, for people on dialysis with high blood phosphate

  This study will test whether the iron-based drug AP301 can lower high blood phosphate in people with end-stage kidney disease who are on maintenance dialysis.

  Recruiting at 41 sites Phase 3 Alebund Pharmaceuticals · Granada Hills, California and 41 other locations · NCT06933472

• AP306 at fixed doses in adults on dialysis with high phosphate

  This trial tests if AP306, taken daily at different doses, can safely lower phosphate levels in adults on maintenance dialysis with hyperphosphatemia.

  Recruiting at 31 sites Phase 2 R1 Therapeutics · Huntsville, Alabama and 30 other locations · NCT06712654

• Understanding how drugs work in children

  This study is trying to find the best and safest doses of certain medications for children and young adults under 21 who are being treated for conditions like COVID-19 and pulmonary arterial hypertension.

  Recruiting at 5 sites Duke University · Phoenix, Arizona and 51 other locations · NCT04278404

• Evaluating phosphate level targets in patients with end-stage kidney disease

  This study tests if lowering blood phosphate levels more strictly helps adults with end-stage kidney disease feel better and reduces their risk of heart problems.

  Recruiting at 94 sites The University of Queensland · Camperdown, New South Wales and 125 other locations · NCT03573089

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.